Skip to content

Effectiveness of Low carb products in mitigating blood sugar spikes in patients with Type 2 Diabetes Mellitus.

A pilot study to evaluate the efficacy and safety of low carb DiabeSmart Atta Additive DiabeSmart South Indian Mixture and DiabeSmart Ultra-low carb atta in lowering hyperglycemia in comparison with standard carbohydrate diet among diabetics and pre diabetics.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/053173
Enrollment
60
Registered
2023-05-26
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: DiabeSmart atta additive: Food prepared using DiabeSmart atta additive will be provided once on Day 2 Intervention2: 1. DiabeSmart atta additive 2. DiabeSmart South Indian Mixture 3.

Sponsors

Bajo Foods Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male and female subjects aged 30-55 years both inclusive. 2. Subjects with history of prediabetes (5.7-6.4%) and Diabetes mellitus â?? type II for 1-15 years. 3. Diabetics with HbA1c >7.5%

Exclusion criteria

Exclusion criteria: 1. History of hypersensitivity to any of the study treatments, excipients, or drugs of similar chemical classes including sulfonylureas and meglitinides 2. History of type 1 diabetes 3. Subjects on insulin therapy 4. Subjects with the history of uncontrolled hypertension and/or hyperthyroidism 5. History of alcoholism 6. Subjects with psychiatric or neurological disability or mental health disorder 7. Subjects with serious health conditions such as cardiac disease, renal dysfunction, and cancers. 8. Female subjects who are pregnant or had planned for pregnancy in the following months or were breast-feeding. 9. Subjects who refuse to sign informed consent. 10. Those who have participated in another clinical trial within 1 month of visit 1 or plan to participate during the clinical trial period. 11. According to the investigatorâ??s opinion, participants who are deemed unable to comply with the test requirements or otherwise deemed unsuitable. 12. Any planned surgery during study.

Design outcomes

Primary

MeasureTime frame
1. Fasting Blood Sugar Test 2. Post-prandial blood glucoseTimepoint: 1. Baseline on day 1 and day 2 2. At 1 hr and 2 hr post each product consumption on day 1 and day 2

Secondary

MeasureTime frame
Occurrence of any AETimepoint: Day 1 and Day 2

Countries

India

Contacts

Public ContactSubham Dutta

Syncorp Health Pvt Ltd

sujay.gowda@syncorphealth.com9110224495

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026